Hi Led.

I am very pleased to have the new Zack's coverage out there esp as a buy reco with potential for $3.25. IMHO it is better to have some coverage than none and it is just another tool to put RVX on the radar.

I want to say thanks to you for putting Zacks into perspective. You have a wealth of trading perspective. Your experiences and perspectives are very valuable and I for one truly appreciate your candid opinions. So don't back off and don't sensor yourself.

I do believe that RVX has a wonderful story to tell and they are getting out their and telling it. On the investment side we've had the Richmond Club, The Yale Club, Cavendish and many, many scientific conferences and presentations. I believe scientific papers are coming soon. So Resverlogix is doing the right things by getting the message out to key audiences (scientific and investment). Yet none of this has even budged the share price (or perhaps the activity is holding it from falling further).

From my perspective everything that has happened in the past many years has been positive (the RCT/PAV end point in ASSURE was unfortunate but right for what they new at the time). We've seen very rapid understanding in the MOA of rvx-208 and the messages from this are extremely positive. Keep in mind that they could have found negative information but in fact the indications were expanded based on the new understanding. The steering committee for BETonMACE is filled with the highest level scientists.

I am long because of the science and I'm building because of the exceptionally low share price.

So what I see is it is time to sit back until late 2018 and then get ready to party. In the mean time;

1. RVX will gain further understanding of the MOA of rvx-208 and perhaps it's derivatives/cousins.
2. Orphan trials will start and may result in early revenue.
3. There may be new regional partnerships.
4. The scientific interest in epigenetics will accelerate and develop strong momentum. This may help RVX gain credibility OR RVX may be surpassed???
5. Zenith will develop and test it's epigenetic platforms further and will understand them quicker because of the new diagnostic tools being utilized.
6. The continuing communications by RVX may result in more high profile analysts covering it.
7. Etc.

So stay healthy, manage your cash flow and make sure you have a good blue chip component to your portfolio, have fun and plan what you are going to do with your windfall when the blockbuster hits in 2018.

Good luck to all and thanks again ledenfrog... stay objective as always.

Cheers

Toinv

P.S. - I'm not usually one to predict but here is my prediction for what Don will say regarding a Zenith NASDAQ IPO at the Dec 21 meeting. He will say " we have studied an IPO for Zenith but biotech has been hit hard and we will wait until market conditions are more favourable".